0001694665-23-000178.txt : 20231108
0001694665-23-000178.hdr.sgml : 20231108
20231108203228
ACCESSION NUMBER: 0001694665-23-000178
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231107
FILED AS OF DATE: 20231108
DATE AS OF CHANGE: 20231108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McHale Duncan
CENTRAL INDEX KEY: 0001738896
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38473
FILM NUMBER: 231389720
MAIL ADDRESS:
STREET 1: C/O EVELO BIOSCIENCES, INC.
STREET 2: 620 MEMORIAL DRIVE, SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Evelo Biosciences, Inc.
CENTRAL INDEX KEY: 0001694665
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 465594527
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE, 600/700, SUITE 7-201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-577-0300
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE, 600/700, SUITE 7-201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
wk-form4_1699493537.xml
FORM 4
X0508
4
2023-11-07
0
0001694665
Evelo Biosciences, Inc.
EVLO
0001738896
McHale Duncan
C/O EVELO BIOSCIENCES, INC.
ONE KENDALL SQUARE, 600/700, SUITE 7-201
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
1
Common Stock
2023-11-07
4
M
0
6500
A
20087
D
Common Stock
2023-11-08
4
S
0
3103
0.33
D
16984
D
Restricted Stock Units
2023-11-07
4
M
0
6500
0
D
Common Stock
6500
6500
D
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $0.32 to $0.34, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the Reporting Person's continued service to the issuer on each such vesting date. These RSUs have no expiration date.
/s/ Marella Thorell, Attorney-in-Fact for Duncan McHale
2023-11-08